Articles related to CONTROLLED MEDICINES

Explore the DEA’s latest regulations on electronic prescriptions for controlled substances, a significant step towards modernizing pharmacy practices. Learn more about how these changes may impact the way prescriptions are transferred and managed, aligning with current technological advancements and legal requirements.

The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.

Uncover the sweeping developments in telemedicine prescribing of controlled substances and how they impact your pharmacy. The DEA and SAMHSA recently extended the ability for clinicians to prescribe controlled medications through telemedicine until November 11, 2023. Initially, this extension was set to expire on May 11, 2023, as the COVID-19 Public Health Emergency (PHE) ended. Previously, in-person visits were necessary for these prescriptions. The new rule offers continuity of care for patients, according to Christopher M. Jones, the Director of the CDC’s National Center for Injury Prevention and Control. The rule might be extended or shortened depending on when the DEA and SAMHSA’s final regulation is effective. In March, these agencies had proposed reverting to the initial in-person prescribing requirement for controlled medications. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 instated this requirement to mitigate the risk of dependence on these medications. However, the agencies received almost 40,000 comments when they proposed to reinstate in-person visits, many emphasizing the benefits of telemedicine. Telemedicine enables more individuals to access treatments they otherwise couldn’t. This feedback has influenced the decision to maintain the telemedicine option for at least another six months. This extension gives the agencies time to consider […]